ibrutinib,venetoclax,pirtobrutinib
eli lilly,abbvie,janssen,roche
['venetoclax', ' ibru', 'pirto']
ibr-ven in upfront wm
oral agents 2yr duration
pros ph ii
n=45 ventricular arrhyth 9% inc 2 deaths (despite pr/vgpr) -&gt; halted study median exposure 11 months
vgpr 40% but no cr
future studies: pirto-ven - cardiac safety clear concern
mechanism #ash2022 castillo et al 